tiprankstipranks
Applied Therapeutics Inc (APLT)
NASDAQ:APLT
US Market

Applied Therapeutics (APLT) Stock Forecast & Price Target

Compare
741 Followers
See the Price Targets and Ratings of:

APLT Financial Forecast

APLT Earnings Forecast

Next quarter’s earnings estimate for APLT is -$0.16 with a range of -$0.16 to -$0.16. The previous quarter’s EPS was -$0.20. APLT beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.33% of the time in the same period. In the last calendar year APLT has Outperformed its overall industry.
Next quarter’s earnings estimate for APLT is -$0.16 with a range of -$0.16 to -$0.16. The previous quarter’s EPS was -$0.20. APLT beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.33% of the time in the same period. In the last calendar year APLT has Outperformed its overall industry.

APLT Sales Forecast

Next quarter’s sales forecast for APLT is $3.75M with a range of $3.75M to $3.75M. The previous quarter’s sales results were ―. APLT beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 46.72% of the time in the same period. In the last calendar year APLT has Outperformed its overall industry.
Next quarter’s sales forecast for APLT is $3.75M with a range of $3.75M to $3.75M. The previous quarter’s sales results were ―. APLT beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 46.72% of the time in the same period. In the last calendar year APLT has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair
Hold
Downgraded
12/23/24
William Blair downgrades Applied Therapeutics (APLT) to a Hold
Leerink Partners
Buy
Reiterated
12/20/24
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
RBC Capital
$12$1.5
Hold
265.85%
Upside
Reiterated
12/20/24
RBC Capital Reaffirms Their Hold Rating on Applied Therapeutics (APLT)
Citi
$8
Buy
1851.22%
Upside
Assigned
11/29/24
Applied Therapeutics price target raised to $13 from $11 at CitiApplied Therapeutics price target raised to $13 from $11 at Citi
Robert W. Baird
$14$5
Buy
1119.51%
Upside
Reiterated
11/29/24
Applied Therapeutics price target lowered to $5 from $14 at BairdApplied Therapeutics price target lowered to $5 from $14 at Baird
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair
Hold
Downgraded
12/23/24
William Blair downgrades Applied Therapeutics (APLT) to a Hold
Leerink Partners
Buy
Reiterated
12/20/24
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
RBC Capital
$12$1.5
Hold
265.85%
Upside
Reiterated
12/20/24
RBC Capital Reaffirms Their Hold Rating on Applied Therapeutics (APLT)
Citi
$8
Buy
1851.22%
Upside
Assigned
11/29/24
Applied Therapeutics price target raised to $13 from $11 at CitiApplied Therapeutics price target raised to $13 from $11 at Citi
Robert W. Baird
$14$5
Buy
1119.51%
Upside
Reiterated
11/29/24
Applied Therapeutics price target lowered to $5 from $14 at BairdApplied Therapeutics price target lowered to $5 from $14 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

APLT Analyst Recommendation Trends

Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
8
7
5
5
3
Buy
1
3
4
8
8
Hold
0
0
0
1
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
10
9
14
15
In the current month, APLT has received 11 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. APLT average Analyst price target in the past 3 months is $1.50.
Each month's total comprises the sum of three months' worth of ratings.

APLT Stock Forecast FAQ

What is APLT’s average 12-month price target, according to analysts?
Based on analyst ratings, Applied Therapeutics Inc’s 12-month average price target is $1.50.
    What is APLT’s upside potential, based on the analysts’ average price target?
    Applied Therapeutics Inc has 265.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is APLT a Buy, Sell or Hold?
          Applied Therapeutics Inc has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Applied Therapeutics Inc’s price target?
            The average price target for Applied Therapeutics Inc is $1.50. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1.50 ,the lowest forecast is $1.50. The average price target represents 265.85% Increase from the current price of $0.41.
              What do analysts say about Applied Therapeutics Inc?
              Applied Therapeutics Inc’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of APLT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis